Loading
A phase 3 trial of Rinatabart sesutecan in endometrial cancer, run by Genmab, now recruiting.
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer is a phase 3 interventional study registered as NCT07166094 by Genmab, with 660 participants planned, started 2025-11-28 and due to reach its primary completion in 2029-08. Interventions recorded: Rina-S, IC. Conditions listed: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab.
Shares Genmab, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/